Clinical Trial

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this study is to assess the incidence of the composite of thrombotic events (TEs) and thromboembolic events (TEEs) in patients with congenital antithrombin deficiency under when they receive Atenativ for surgical procedures or parturition.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2021-06-04; most recent amendment 2026-06-02.
Status change: Not Yet Recruiting → Recruiting 2022-07-27
Trial Details
NCT Number NCT04918173
Lead Sponsor Octapharma
Conditions Congenital Antithrombin Deficiency
Enrollment 38 participants
Start Date 2022-07-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-03